Nuvalent, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUVL research report →
Companywww.nuvalent.com
Nuvalent, Inc. , a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
- CEO
- James R. Porter
- IPO
- 2021
- Employees
- 162
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $7.53B
- P/E
- -17.88
- P/S
- 0.00
- P/B
- 6.85
- EV/EBITDA
- -20.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -42.78%
- ROIC
- -35.11%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-425,377,000 · -63.13%
- EPS
- $-5.85 · -48.85%
- Op Income
- $-414,307,000
- FCF YoY
- -48.71%
Performance & Tape
- 52W High
- $113.02
- 52W Low
- $70.25
- 50D MA
- $102.04
- 200D MA
- $96.26
- Beta
- 1.15
- Avg Volume
- 569.76K
Get TickerSpark's AI analysis on NUVL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Porter James Richard | other | 30,000 |
| May 4, 26 | Porter James Richard | sell | 1,699 |
| May 4, 26 | Porter James Richard | sell | 1,408 |
| May 4, 26 | Porter James Richard | sell | 7,429 |
| May 4, 26 | Porter James Richard | sell | 17,353 |
| May 4, 26 | Porter James Richard | sell | 2,111 |
| May 4, 26 | Porter James Richard | other | 30,000 |
| May 1, 26 | Balcom Alexandra | other | 7,159 |
| May 1, 26 | Balcom Alexandra | other | 4,271 |
| May 1, 26 | Balcom Alexandra | sell | 3,872 |
Our NUVL Coverage
We haven't published any research on NUVL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NUVL Report →